1. Home
  2. RGLS vs KOPN Comparison

RGLS vs KOPN Comparison

Compare RGLS & KOPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RGLS
  • KOPN
  • Stock Information
  • Founded
  • RGLS 2007
  • KOPN 1984
  • Country
  • RGLS United States
  • KOPN United States
  • Employees
  • RGLS N/A
  • KOPN N/A
  • Industry
  • RGLS Biotechnology: Pharmaceutical Preparations
  • KOPN Semiconductors
  • Sector
  • RGLS Health Care
  • KOPN Technology
  • Exchange
  • RGLS Nasdaq
  • KOPN Nasdaq
  • Market Cap
  • RGLS 102.8M
  • KOPN 107.6M
  • IPO Year
  • RGLS 2012
  • KOPN 1992
  • Fundamental
  • Price
  • RGLS $1.59
  • KOPN $0.89
  • Analyst Decision
  • RGLS Strong Buy
  • KOPN Strong Buy
  • Analyst Count
  • RGLS 6
  • KOPN 3
  • Target Price
  • RGLS $10.33
  • KOPN $2.67
  • AVG Volume (30 Days)
  • RGLS 278.0K
  • KOPN 438.2K
  • Earning Date
  • RGLS 11-07-2024
  • KOPN 11-07-2024
  • Dividend Yield
  • RGLS N/A
  • KOPN N/A
  • EPS Growth
  • RGLS N/A
  • KOPN N/A
  • EPS
  • RGLS N/A
  • KOPN N/A
  • Revenue
  • RGLS N/A
  • KOPN $41,545,194.00
  • Revenue This Year
  • RGLS N/A
  • KOPN $22.02
  • Revenue Next Year
  • RGLS N/A
  • KOPN $13.55
  • P/E Ratio
  • RGLS N/A
  • KOPN N/A
  • Revenue Growth
  • RGLS N/A
  • KOPN N/A
  • 52 Week Low
  • RGLS $1.08
  • KOPN $0.67
  • 52 Week High
  • RGLS $3.79
  • KOPN $2.82
  • Technical
  • Relative Strength Index (RSI)
  • RGLS 47.92
  • KOPN 47.30
  • Support Level
  • RGLS $1.47
  • KOPN $0.88
  • Resistance Level
  • RGLS $1.65
  • KOPN $0.96
  • Average True Range (ATR)
  • RGLS 0.10
  • KOPN 0.06
  • MACD
  • RGLS 0.00
  • KOPN -0.00
  • Stochastic Oscillator
  • RGLS 48.84
  • KOPN 36.35

About RGLS Regulus Therapeutics Inc.

Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development.

About KOPN Kopin Corporation

Kopin Corp is a provider of high-performance application-specific optical solutions consisting of high-resolution microdisplays and optics, subassemblies, and headsets. It serves soldiers, avionics, armored vehicles training and simulation military applications, and others. Its product portfolio includes Microdisplays, Spatial Light Modulators, Optical Modules, Medical, Training, and Simulation. Geographically, it derives a majority of its revenue from the Americas and also has a presence in Asia-Pacific; Europe, and Other Countries.

Share on Social Networks: